65,437 trials
Prostatic Neoplasm
Primary: Effectiveness Parameter for Staging of Prostate Cancer: Metastases at Each Visit — 782; 59; 45; 28 participants
Advanced Solid Tumors
Primary: Maximum Tolerated Dose (MTD) — 5 mg BID
Double Lumen Tube Intubation
Primary: Number of Successfull Primary Placement of the Double Lumen Tube. — 49 Participants
Osteoarthritis · Rheumatoid Arthritis · Post-traumatic Arthritis
Primary: Knee Active Flexion — 119.2 degrees
Hypertension
Primary: Central Aortic Blood Pressure — -16.1; -16.0 mmHg
Cholelithiasis
Primary: Number of Participants With Subhepatic Collection at Ultrasonographic Examination — 45; 46 Participants
Asthma
Primary: Change From Baseline in Mean Morning Peak Expiratory Flow (PEF) Over Weeks 5-12 — 59.21; 50.98 Liters per minute (L/min) — p=0.683
Skin Neoplasms · Kidney Transplantation
Primary: New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year — 1.31; 2.48 Standardized Yearly Rate of NMSC — p=0.022
Opioid-Related Disorders · Opiate Dependence · Drug Abuse
Primary: Retention Rate — 57.3; 45.6 percentage of patients
Infections, Papillomavirus
Primary: Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms — 46; 18; 19; 2 Participants
Hyperlipidemia
Primary: Percentage of Participants With Positive Response on Increased Motivation Using a Self-test at Month 12 — 36.2 Percentage of participants
Contact Lens Care
Primary: Solution-Related Corneal Staining — 0 Percentage of participants
ADHD
Primary: Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 7 Weeks — -24.3; -18.7; -5.7 Scores on a…
Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Response Rate (Complete Response (CR) or Partial Response (PR)) — 1 participants
Hypercholesterolemia
Primary: Number of Participants Achieving Individual LDL Cholesterol (LDL-C) Target Level — 678 Participants